ACTRN12617001561370已完成1 期
A Phase 1 Exploratory Placebo and Active-Controlled, Double-Blind, Single and Multiple-Dose Escalation, Pharmacokinetic, Pharmacodynamic and Food Effect Study of CNSA-001 in Healthy Volunteers
Censa Pharmaceuticals Australia Pty Ltd0 个研究点目标入组 83 人开始时间: 2017年11月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 83
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 —（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
A Phase 1, Randomized, Placebo- and Active-Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of VX-661 on the QT/QTc Interval in Healthy Subjects10038686cystic fibrosisNL-OMON42529Vertex Pharmaceuticals130
已完成
不适用
A Phase 1, Randomized, Placebo- and Active-Controlled, Double-Blind, 4-Period Crossover ECG Study to Evaluate the Effect of VX 509 on QT/QTc Interval in Healthy Adult Subjectsautoimmune disorders10003816Rheumatoid arthritisNL-OMON37134Vertex Pharmaceuticals80
已完成
不适用
A Placebo- and Active-Controlled Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Subjects With Major Depressive DisorderMajor depressive disorder10027946depressionNL-OMON43083Janssen-Cilag30
已完成
3 期
Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in COPD Patients With Moderate to Severe Airflow LimitatioCTRI/2012/12/003207ovartis Healthcare Pvt Ltd1,224
进行中（未招募）
不适用
Comparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in Chronic Obstructive Pulmonary Disease patients with moderate to severe airflow limitatioChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-002057-38-SIovartis Pharma Service AG1,224